logo

For the Inventor, By the Inventor

Tokyo, Japan

Japanese Foundation for Cancer Research


USPTO Granted Patents = 56



Forward Citations = 141

Loading Chart...
Loading Chart...

131 inventors (with patents filed for the assignee):

goldMedal Takeshi Ohashi (8 out of 46 patents)

silverMedal Kengo Takeuchi (8 out of 8 patents)

bronzeMedal Naoya Fujita (7 out of 13 patents)

4.  Haruo Sugano (6 out of 17 patents)

5.  Kiyotaka Shiba (5 out of 15 patents)

6.  Ryohei Katayama (5 out of 5 patents)

7.  Kohei Miyazono (5 out of 29 patents)

8.  Masahiro Kawabata (4 out of 4 patents)

9.  Hiroyuki Seimiya (3 out of 3 patents)

10.  Takuya Narihira (3 out of 9 patents)

11.  Seiji Sakata (3 out of 3 patents)

12.  Yuki Togashi (3 out of 7 patents)

13.  Tadatsugu Taniguchi (3 out of 23 patents)

14.  Takashi Tsuruo (3 out of 10 patents)

15.  Yoko Yashiroda (2 out of 2 patents)


Core Competencies:
Extracellular Vesicles
Pathological Diagnosis
Artificial Intelligence
Cancer Therapeutics
EGFR Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Biomarkers
Image Processing
Cancer Screening
Cellular Immunity
Fusion Proteins
Interleukin-2 Polypeptides

56 patents:

1. 12264352 - Method for enhancing extracellular vesicle production (2025-04-01),
2. 12205723 - Pathological diagnosis assisting method using AI, and assisting device (2025-01-21),
3. 12198811 - Pathology image management system (2025-01-14),
4. 12055538 - Fusions and method for detecting same (2024-08-06),
5. 11817202 - Information processing apparatus, information processing method, and program (2023-11-14),
6. 11781115 - Primary culture method (2023-10-10),
7. 11633084 - Image diagnosis assistance apparatus, data collection method, image diagnosis assistance method, and image diagnosis assistance program (2023-04-25),
8. 11566017 - Dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor (2023-01-31),
9. 11530266 - Anti-podoplanin antibody (2022-12-20),
10. 11419871 - Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance (2022-08-23),
11. 11415584 - Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug (2022-08-16),
12. 11414429 - Compound or pharmaceutically acceptable salt thereof (2022-08-16),
13. 11340215 - Screening method of anticancer agent focused on function of HP1 and evaluation system (2022-05-24),
14. 11286261 - Fourth-generation EGFR tyrosine kinase inhibitor (2022-03-29),
15. 11152105 - Information processing apparatus, information processing method, and program (2021-10-19),
The Japanese Foundation for Cancer Research (JFCR) is a non-profit organization dedicated to advancing cancer research and improving cancer care in Japan. With a mission to eradicate cancer, JFCR conducts innovative research, promotes international collaborations, and provides support for cancer patients and their families. Through its extensive network of researchers, clinicians, and medical institutions, JFCR strives to develop effective treatments and preventive measures against cancer, contributing to the global fight against this devastating disease.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

56 Patents

#663 in Tokyo

#1,571 in Japan

#12,433 in the World

...
Tokyo, Japan

Japanese Foundation for Cancer Research

Forward Citations = 141

131 inventors:

goldMedal Takeshi Ohashi (8 out of 46 patents)

silverMedal Kengo Takeuchi (8 out of 8 patents)

bronzeMedal Naoya Fujita (7 out of 13 patents)

4.  Haruo Sugano (6 out of 17 patents)

5.  Kiyotaka Shiba (5 out of 15 patents)

Please report any incorrect information to support@idiyas.com
Loading…